Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP103 Extension in Mitochondrial Disease
NCT02473445Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cysteamine in inherited mitochondrial disease, sponsored by Amgen. Started May 2015; status: terminated.
02
Drugs
cysteamine
03
Conditions
inherited mitochondrial disease
Beyond the preview
Go deeper on NCT02473445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473445.